Philippe Maria Clotaire Margaron
University of British Columbia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Hotspot
Dive into the research topics where Philippe Maria Clotaire Margaron is active.
Publication
Featured researches published by Philippe Maria Clotaire Margaron.
Biochimica et Biophysica Acta | 1997
Philippe Maria Clotaire Margaron; Rob Sorrenti; Julia G. Levy
Adhesion is a primordial cell function that, among others, regulates inflammation, metastasis, and tissue repair. To understand how these events could be affected by photodynamic therapy (PDT), we studied the effects of PDT on human foreskin fibroblast (HFF) adhesion to bovine collagen type I, human vitronectin or fibronectin. PDT, using benzoporphyrin derivative monoacid ring A (verteporfin) as the photosensitizer, inhibited cell adhesion in a drug dose-dependent manner, with no significant difference among matrices. The drug dose that killed 90% of cells within 20 h post-treatment inhibited HFF adhesion by 55%-68%. However, 45 min following PDT, a time period corresponding to that of the adhesion assay, HFF membrane integrity remained unaltered. In addition, cell surface expression of integrins was not modified for at least 2h following PDT. Western blots of cell lysates, using the anti-phosphotyrosine 4G10 monoclonal antibody, revealed that PDT prevented the adhesion-induced phosphorylation of 110-130 kDa proteins. Immunoblots of cell lysates immunoprecipitated with antibodies to focal adhesion kinase suggested that its phosphorylation was suppressed by PDT. These results demonstrate that PDT inhibits cell adhesion and affects integrin signalling without modifying cell membrane integrity or integrin expression.
Journal of Investigative Surgery | 2000
Robert G. Turnbull; Jerry C. Chen; Rosalind S. Labow; Philippe Maria Clotaire Margaron; York N. Hsiang
Benzoporphyrin derivative monoacid ring A (Verteporfin, BPD-MA), a photosensitizing drug, has been suggested as having inhibitory effects on smooth muscle cell (SMC) proliferation in rabbit aortic intimal injuries. The effect of BPD-MA on vascular SMCs in the absence of light stimulation in vitro and in vivo was studied using models of intimal hyperplasia. Human SMCs were incubated with BPD-MA for 4 h in darkness. A small (20%) but significant decrease in viability (n =42,p < .05) was noted for BPD-MA concentrations above 15 microg/mL. This was an all-or-none phenomenon with no further decrease in viability at higher concentrations. Treatment with BPD-MA was also carried out in vivo using a balloon injury model of intimal hyperplasia in rabbit aortas. Thirty-three rabbits were randomized into five groups and given intravenous BPD-MA (2 mg/kg) according to the following schedule: Group 1 (n = 8), BPD-MA 25 min prior to injury; Group 2 (n = 8), BPD-MA 25 min prior to injury plus a second dose 4 weeks later; Group 3 (n = 4), BPD-MA immediately postinjury; Group 4 (n = 7), BPD-MA immediately postinjury plus a second dose 4 weeks later; or Group 5 (n = 6), no drug (control group). No statistically significant difference was seen in the amount of intimal hyperplasia that developed in the five groups.ABSTRACT Benzoporphyrin derivative monoacid ring A (Verteporfin, BPD-MA), a photosensitizing drug, has been suggested as having inhibitory effects on smooth muscle cell (SMC) proliferation in rabbit aortic intimal injuries. The effect of BPD-MA on vascular SMCs in the absence of light stimulation in vitro and in vivo was studied using models of intimal hyperplasia. Human SMCs were incubated with BPDMA for 4 h in darkness. A small (20%) but significant decrease in viability (n = 42, p < .05) was noted for BPD-MA concentrations above 15 mu g/mL. This was an all-or-none phenomenon with no further decrease in viability at higher concentrations. Treatment with BPD-MA was also carried out in vivo using a balloon injury model of intimal hyperplasia in rabbit aortas. Thirty-three rabbits were randomized into five groups and given intravenous BPD-MA (2 mg/kg) according to the following schedule: Group 1 (n = 8), BPD-MA 25 min prior to injury; Group 2 (n = 8), BPD-MA 25 min prior to injury plus a second dose 4 weeks later; Group 3 (n = 4), BPD-MA immediately postinjury; Group 4 (n = 7), BPD-MA immediately postinjury plus a second dose 4 weeks later; or Group 5 (n = 6), no drug (control group). No statistically significant difference was seen in the amount of intimal hyperplasia that developed in the five groups.
Archive | 2002
Philippe Maria Clotaire Margaron; Anna M. Richter; Julia G. Levy
Archive | 1998
Modestus Obochi; Philippe Maria Clotaire Margaron; Christopher R. Honey; Stephen Yip; Julia G. Levy
Archive | 1999
York N. Hsiang; A.M.J. Buchan; Julia G. Levy; Philippe Maria Clotaire Margaron
Archive | 2000
Beth Anne Allison; Philippe Maria Clotaire Margaron; York N. Hsiang
Archive | 1999
Philippe Maria Clotaire Margaron; Simon Leong; Julia G. Levy; Anna M. Richter
Archive | 1998
Barbara Kelly; Julia G. Levy; Philippe Maria Clotaire Margaron
Archive | 2000
Beth Anne Allison; Philippe Maria Clotaire Margaron; Valery Rubinchik; Russell G. Hodge; Michael David Leslie Stonefield
Journal of Neurosurgery | 2000
Christopher R. Honey; Modestus Obochi; Hao Shen; Philippe Maria Clotaire Margaron; Stephen Yip; Julia G. Levy